×
About 573 results

ALLMedicine™ Blastic Plasmacytoid Dendritic Cell Center

Research & Reviews  191 results

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-C...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051102
Nature Communications; Cai T, Gouble A et. al.

Apr 29th, 2022 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with poor outcomes with conventional therapy. Nearly 100% of BPDCNs overexpress interleukin 3 receptor subunit alpha (CD123). Given that CD123 is differentially ...

Loss of METTL3 Attenuates Blastic Plasmacytoid Dendritic Cell Neoplasm Response to PRMT...
https://doi.org/10.1182/bloodadvances.2021006306
Blood Advances; Rethnam M, Tan DQ et. al.

Apr 29th, 2022 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with poor clinical outcomes. Dysregulated MYC expression, which is associated with protein arginine methyltransferase 5 (PRMT5) dependency, is a r...

Immunoblastoid blastic plasmacytoid dendritic cell neoplasm with MYC rearrangement.
https://doi.org/10.1182/blood.2021015236
Blood Yu YT, Chang KC

Apr 8th, 2022 - Immunoblastoid blastic plasmacytoid dendritic cell neoplasm with MYC rearrangement.|2022|Yu YT,Chang KC,|genetics,

see more →

Drugs  2 results see all →

Clinicaltrials.gov  2 results

A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies
https://clinicaltrials.gov/ct2/show/NCT02623439

Oct 14th, 2020 - Study Design: This is a single center Phase 2 study of myeloablative (MA) and nonmyeloablative (NMA) conditioning, transplantation of partially HLA-mismatched bone marrow or peripheral blood stem cells and post-transplantation cyclophosphamide (Cy...

Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN)
https://clinicaltrials.gov/ct2/show/NCT02859623

Aug 9th, 2016 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease characterized by an aggressive clinical behavior and a poor prognosis. It predominantly affects elderly males with an average age of 67 years at diagnosis and the affected orga...

see more →

News  34 results

Isolated Nodule and Generalized Lymphadenopathy
https://www.mdedge.com/dermatology/article/252525/dermatopathology/isolated-nodule-and-generalized-lymphadenopathy
Yahya Daneshbod, MD, Michael Greas, MD et. al.

Mar 8th, 2022 - The Diagnosis: Blastic Plasmacytoid Dendritic Cell Neoplasm A diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) was rendered. Subsequent needle core biopsy of a left axillary lymph node as well as bone marrow aspiration and biopsy.

Tagraxofusp and Hyper-CVAD Represent Treatment Options for Patients with BPDCN
https://www.onclive.com/view/tagraxofusp-and-hyper-cvad-represent-treatment-options-for-patients-with-bpdcn

Feb 3rd, 2022 - Despite the rarity of patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), 2 studies examining treatment options for the disease produced encouraging results and safety data, according to Naveen Pemmaraju, MD. Pemmaraju p...

Dr. Pemmaraju on the Ongoing Trial of Tagraxofusp in Myelofibrosis
https://www.onclive.com/view/dr-pemmaraju-on-the-ongoing-trial-of-tagraxofusp-in-myelofibrosis

Oct 6th, 2021 - Naveen Pemmaraju, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the ongoing phase I/II trial of tagraxofusp (SL-401; Elzonris) in patients with intermedia...

Dr. Pemmaraju on the Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasms
https://www.onclive.com/view/dr-pemmaraju-on-the-trial-of-sl401-in-blastic-plasmacytoid-dendritic-cell-neoplasms

Oct 6th, 2021 - Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the trial of SL-401 in blastic plasmacytoid dendritic cell neoplasms (BPDCL). SL-401 is a novel agent under in...

Rare hematologic malignancy may first present to a dermatologist
https://www.mdedge.com/dermatology/article/246549/rare-diseases/rare-hematologic-malignancy-may-first-present-dermatologist
Doug Brunk

Sep 23rd, 2021 - Dermatologists may be the first clinicians to diagnose blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare, aggressive hematologic malignancy that involves the skin in about 80% of cases. Courtesy Dr.

see more →